Merck and Pfizer back a Michigan startup's mission to advance tumor profiling

With the support of Thermo Fisher executives and the help of a couple experts in the field, Rhodes launched Strata Oncology to advance DNA and RNA sequencing. The team has since attracted some impressive backers, including both Pfizer and Merck. And on Wednesday, they unveiled a $90 million Series C round to build out a commercial team and fuel clinical trials for new RNA-based treatment selection tests.